1. Finding patients with pancreatic cancer (in all stages), before any treatment.
2. Non invasively quantify fatty infiltration of pancreas using, MRI DIXON Scan in pancreatic cancer patient relatively to liver.
3. Measuring cell-free blood DNA in those patients for evaluating the aggressiveness of the disease.
4. Quantify the prognostic significance of pancreatic steatosis in comparison with clinical and pathological prognostic indexes used today.
